At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Liquid Biopsy System (LBS) (device)
- How long the study runs
- Study runs about 53 months (dates as stated)
- About the drug or intervention
- Liquid Biopsy System (LBS) — device: Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 300
- Started
- 2023-09-14
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for coronary artery disease
- • NA - 300 participants
- • The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with coronary artery disease
Where?
- • Bournemouth - Royal Bournemouth Hospital
- • Bristol - Bristol Heart Institute
- • Cambridge - Royal Papworth Hospital
- • Norwich - Norfolk and Norwich Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. Using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Stage 1 screening inclusion:
- ✓≥18 years of age, have capacity and be willing to provide agreement to take part to participate
- ✓Clinical evidence of obstructive coronary artery disease and be scheduled for either:
- ✓Elective coronary angiography +/- proceed for stable angina OR
- ✓Elective PCI for stable angina with known bystander disease OR
Who cannot take part
- ✗Stage 1 screening exclusion:
- ✗Myocardial Infarction within 30 days of procedure.
- ✗Chronic kidney failure (eGFR\<30ml/min/1.73m2).
- ✗Contrast allergy.
- ✗Hypotension, shock or haemodynamic instability.
See the full criteria
Where Is This Study? (4 UK sites)
Royal Bournemouth Hospital
Bournemouth, United Kingdom
Bristol Heart Institute
Bristol, United Kingdom
Royal Papworth Hospital
Cambridge, United Kingdom
Norfolk and Norwich Hospital
Norwich, United Kingdom
How to Get in Touch
Clinical Project Manager
Sponsor contactCONTACT
PlaqueTec General Manager
Sponsor contactCONTACT
